HIMS Stock: 75% Crash vs 150% Analyst Upside

Hims & Hers Health has experienced a brutal 75.50% decline from its May 2025 peak of $64.65, transforming from a market darling into what many investors now consider a nightmare holding. The telehealth provider's dramatic fall accelerated in late September 2025 but intensified significantly in early 2026.

The catalyst for the recent collapse came on February 9, 2026, when pharmaceutical giant Novo Nordisk filed a major lawsuit against Hims & Hers. The legal action accuses the company of illegally marketing unapproved versions of Novo's FDA-approved semaglutide medications, which are used for weight loss and diabetes treatment.

Novo Nordisk's lawsuit alleges that Hims & Hers deceived patients and endangered public health by selling compounded drugs that infringe on Novo's patents. The pharmaceutical company is seeking a permanent injunction to stop these sales and recover unspecified damages for patent infringement.

Despite this legal turmoil, the stock's technical indicators suggest extreme oversold conditions. The Relative Strength Index (RSI) reading of 16.87 is well below the 30 threshold that typically indicates a stock is due for a rebound. Meanwhile, short interest, while still high at 40.98%, has been cut in half since October 2025.

This legal battle matters because it strikes at the heart of Hims & Hers' growth strategy in the lucrative GLP-1 weight loss drug market. If Novo Nordisk succeeds in permanently blocking HIMS from selling compounded semaglutide, the company could lose access to one of healthcare's fastest-growing segments.

However, the broader telehealth market remains exceptionally strong. Industry forecasts project 24.68% annual growth through 2030, reaching $455 billion globally. Hims & Hers' core businesses in hair care and sexual wellness are also positioned in markets growing at 10-11% annually.

The company's fundamental growth story remains intact outside the GLP-1 controversy. Analysts expect record quarterly revenue of $619 million when HIMS reports on February 23, with earnings returning to positive territory. The company has averaged 82% revenue growth over the past four quarters.

From a valuation perspective, the extreme sell-off has created a potential opportunity. The average analyst price target of $39.32 represents nearly 150% upside, while even the most conservative target of $16.50 suggests some recovery from current levels. The company's debt-to-equity ratio of 1.67 remains manageable despite the stock price collapse.